Heartfelt with Dr Melissa Walton-Shirley

View all posts »

PPI and clopidogrel warning: FDA, next time, please phone a friend

Dec 6, 2009 22:48 EST


As predicted, we are already hearing from panicked patients who wonder if they need to stop their proton-pump inhibitor (PPI). I told my nurse practitioner to switch the last patient to an H2 blocker until we could work her in to discuss the issue. Although we might brush this off as an annoying turn of events, it's actually a pretty serious indictment of just how far behind our FDA has become on late-breaking clinical trials. It's not just a serious breach of information gathering on behalf of the administration; it's a complete misrepresentation of the facts and hints that someone might be a bit too lazy to stay on top of the issues.

I walked by a friend in the pressroom at the American Heart Association meeting who motioned for me to stop by his laptop. "What do you think about this?" he asked, turning his screen so I could read the headlines "FDA warns about PPI/clopidogrel interaction." "That issue was resolved weeks ago," I replied. I scanned the "warning" and mumbled, "Way to go, FDA," wondering to myself if anyone there had even heard of the acronym COGENT. (COGENT was presented at the TCT meeting in October 2009 and was a randomized trial of around 3000 patients that demonstrated NO INCREASE in cardiac events with the combination.) Annoyed, I rolled my eyes and walked off.

The central question here is this, "How well-informed is our regulatory administration?" If an entire pressroom of international journalists, most of whom are nonphysicians, are 1000 times more well-informed than our own FDA about this topic, how far off the mark are other government entities on terrorist threats, airline safety, or bridge repair? Sometimes, being "behind the door" when information is passed out is not just annoying or cute, it's downright dangerous. Patients could actually stop their PPI, develop an ulcer and bleed based on this unnecessary warning. So far, there isn't one single death confirmed from a combination of PPI and clopidogrel, but stopping either medication or both could be lethal for some patients.

So what exactly are the issues with our FDA these days? If they have "too few" consultants, they need to hire more. If there were no money to fund the thorough research of a topic, I'd recommend they at least Google it before "warning about" or "black-boxing" anything. I'd at least do a street shout-out, kind of like the Cash Cab contestants do before making a big decision about what to do next.

In my 20 years of private practice, this FDA warning takes the cake. Next time, I'd suggest a thorough perusal of the latest data before making any big decisions. If Google-ing the topic or the street "shout-out" fails, they could always phone a friend…perhaps two friends, a well-informed cardiologist or, I'm ashamed to admit, even better, a busy medical journalist.

See:

Cardiologists shocked by new FDA alert on clopidogrel-PPI interaction

COGENT: No CV events but significant GI benefits of PPI omeprazole






Your comments
PPI and clopidogrel warning: FDA, next time, please phone a friend
# 1 of 2
January 3, 2010 08:45 (EST)
OussLaw

I dont think the FDA is misinformed. I believe they are deliberately misrepresenting the evidence. They are doing this in order to undermine Clopidogrel as it is soon to become generic. Use of clopidogrel will no longer become profitable for the pharmaceutical company that makes Plavix. The FDA is doing this on the eve of the introduction of new antiplatelet medications like Prasugrel in order to benefit the phramaceutical company that develops and markets it.
It will be difficult to convince physicians to continue treating with Clopidogrel when the FDA has posted a warning against its use in patients who are on a PPI.

# 2 of 2
January 12, 2010 08:30 (EST)
golftee

OussLaw,

I disagree.  It's a typical governent agency.  always a step behind on processing information and even worse, light years behind in action.

Melissa


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

About Dr Melissa Walton-Shirley
Dr Walton-Shirley performs invasive cardiology, nuclear cardiology, and stress echocardiography in a private practice in Glasgow, KY.

Her chief medical interests are CHF/hypertrophic obstructive cardiomyopathy and the promotion of primary PCI for acute MI. Recently she played a significant role in helping to launch an ambitious pilot study of primary PCI in Kentucky, the Kentucky Primary Angioplasty Pilot Project. She has also participated in the TIMI 19, Duke-HF, NRMI, and CRUSADE trials and is proud to have been an advocate of the first smoke-free initiative in Kentucky (2011). She champions a smoke-free America.

Dr Walton-Shirley received her undergraduate degree at the University of Kentucky and went to medical school and did her residency and fellowship at the University of Louisville. She is married with two daughters. Her interests include singing, writing poetry and songs, fitness, and, of course, theheart.org.